STOCK TITAN
  1. Home
  2. Sec-filings
  3. LIPO
  4. [8-K] LIPELLA PHARMACEUTICALS INC. Reports Material Event

Chapter 11 filing puts Lipella Pharmaceuticals (LIPO) on 363 sale path

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
8-K

Rhea-AI Filing Summary

Lipella Pharmaceuticals Inc. has filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania. The company plans to pursue a Section 363 sale process intended to maximize value for creditors.

Lipella expects to seek customary first-day relief so it can continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits in the ordinary course. The company also cautions that trading in its common stock during the Chapter 11 cases is highly speculative and that trading prices may bear little or no relationship to any ultimate recovery for shareholders.

Positive

  • None.

Negative

  • Lipella Pharmaceuticals has filed voluntary Chapter 11 bankruptcy petitions in the U.S. Bankruptcy Court for the Western District of Pennsylvania, signaling significant financial distress and placing outcomes primarily in a court-supervised restructuring process.
  • The company plans a Section 363 sale process focused on maximizing value for creditors, which often leaves limited or no recovery for existing common shareholders, depending on asset sale proceeds and the capital structure.
  • Lipella explicitly warns that trading in its common stock is highly speculative during the Chapter 11 cases and that trading prices may bear little or no relationship to any eventual recovery, if any, for equity holders.

Insights

Lipella has entered Chapter 11 and plans a 363 sale focused on creditor recovery.

Lipella Pharmaceuticals has commenced voluntary Chapter 11 proceedings in the Western District of Pennsylvania and intends to run a Section 363 sale process. This framework typically involves marketing assets or the business to potential buyers with court oversight, emphasizing outcomes for creditors.

The company states it will request first-day relief to keep operations running, including cash management and employee pay, which can help preserve going-concern value during the process. However, Lipella explicitly warns that its common stock is highly speculative in Chapter 11 and that market prices may not reflect any actual recovery for shareholders.

For stakeholders, the key milestones will be court decisions on first-day motions and subsequent steps in the 363 sale process as the company provides further updates during the restructuring.

Item 1.03 Bankruptcy or Receivership Business
The company or a significant subsidiary has filed for bankruptcy or entered receivership.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Chapter 11 filing date March 30, 2026 Date Lipella announced voluntary petitions for relief
Bankruptcy court Western District of Pennsylvania Venue for Lipella’s Chapter 11 cases
Process type Section 363 sale process Stated approach to maximize value for creditors
Chapter 11 regulatory
"filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code"
Chapter 11 is a U.S. bankruptcy process that lets a financially distressed company keep operating while it reorganizes its debts and business plan under court supervision. Think of it as a formal pause that allows the company to renegotiate payments, shed contracts or assets, and seek a path to profitability instead of being liquidated; investors watch it because it can change the value and priority of claims, equity dilution, or the likelihood of recovery.
363 sale process financial
"intends to undergo a 363 sale process under Chapter 11 in order to maximize value for creditors"
first-day relief regulatory
"expects to seek customary “first-day” relief that, if approved by the Court, would allow it to continue day-to-day operations"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of applicable securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What did Lipella Pharmaceuticals (LIPO) announce in its latest filing?
Lipella Pharmaceuticals announced that it filed voluntary petitions for relief under Chapter 11 of the U.S. Bankruptcy Code. The cases are in the United States Bankruptcy Court for the Western District of Pennsylvania, starting a court-supervised restructuring and potential sale process under Section 363.

How does the Chapter 11 filing affect Lipella Pharmaceuticals’ (LIPO) operations?
Lipella states it expects to seek customary first-day relief to continue day-to-day operations. This includes maintaining existing cash management systems and paying employee wages and benefits in the ordinary course, subject to court approval, in an effort to stabilize operations during restructuring.

What is Lipella Pharmaceuticals’ (LIPO) plan under Chapter 11?
Lipella plans to conduct a Section 363 sale process under Chapter 11 to maximize value for creditors. A 363 sale generally involves marketing assets or the business to potential buyers with court oversight, prioritizing creditor recoveries over existing equity interests.

What warning did Lipella Pharmaceuticals (LIPO) give about its common stock?
Lipella cautioned that trading in its common stock during the Chapter 11 cases is highly speculative and poses substantial risks. It noted that trading prices may bear little or no relationship to the actual recovery, if any, that common shareholders ultimately receive in the restructuring.

Where can investors find more information about Lipella Pharmaceuticals’ Chapter 11 case?
The company indicated that additional information about the Chapter 11 filing, including court filings and other case information, may be available through the Bankruptcy Court’s docket. Lipella also stated it will provide updates as appropriate throughout the restructuring process.
false 0001347242 0001347242 2026-03-30 2026-03-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 30, 2026

 

Lipella Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41575   20-2388040
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

7800 Susquehanna St., Suite 505

Pittsburgh, PA

   15208
(Address of registrant’s principal executive office)   (Zip code)

 

Registrant’s telephone number, including area code: (412) 894-1853

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 1.03 Bankruptcy or Receivership

 

On [Filing Date], [Company Name, Inc.] (the “Company”) and certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Western District of Pennsylvania (the “Bankruptcy Court”).

 

Cautionary Note Regarding Chapter 11 Case

 

The Company cautions that trading in the Company’s common stock during the pendency of the Chapter 11 case is highly speculative and poses substantial risks. Trading prices for the Company’s common stock may bear little or no relationship to the actual recovery, if any, by holders of the Company’s common stock in the Chapter 11 Cases.

 

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release, dated March 30, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: March 30, 2026 Lipella Pharmaceuticals Inc.  
       
  By: /s/ Jonathan Kaufman  
   

Name: Jonathan Kaufman

Title: Chief Executive Officer

  

 

 

Exhibit 99.1

 

 

Press Release

 

FOR IMMEDIATE RELEASE

 

Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11

 

[Pittsburgh, Pennsylvania] — [March 30, 2026] — Lipella Pharmaceuticals Inc. (“Lipella” or the “Company”), a clinical-stage biotechnology company, announced today that it filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Western District of Pennsylvania (the “Court”). The Company intends to undergo a 363 sale process under Chapter 11 in order to maximize value for creditors.

 

In connection with the Chapter 11 cases, the Company expects to seek customary “first-day” relief that, if approved by the Court, would allow it to continue day-to-day operations, including maintaining cash management systems and paying employee wages and benefits in the ordinary course.

 

The Company will provide updates as appropriate throughout the restructuring process.

 

Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, without limitation, statements regarding the Company’s expectations and intentions relating to the Chapter 11 process, ongoing operations, strategic alternatives, and related matters. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others, the Company’s ability to obtain Court approval with respect to motions in the Chapter 11 cases, the Company’s ability to maintain operations during the Chapter 11 process, the effects of the Chapter 11 filing on stakeholders, and other risks and uncertainties described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

 

Additional Information

 

Additional information regarding the Chapter 11 filing, including Court filings and other case information, may be available through the Court’s docket.

 

TADMS:21257425-1:044116-208154

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents